NasdaqGS - Delayed Quote • USD
BioMarin Pharmaceutical Inc. (BMRN)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:48 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 18 | 21 | 21 |
| Avg. Estimate | 0.35 | 0.47 | 1.72 | 2.63 |
| Low Estimate | 0.17 | 0.27 | 0.42 | 1.29 |
| High Estimate | 0.45 | 0.6 | 2.12 | 4.04 |
| Year Ago EPS | 0.29 | 0.21 | 0.87 | 1.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 23 | 23 | 28 | 27 |
| Avg. Estimate | 662.02M | 692.02M | 2.76B | 3.1B |
| Low Estimate | 651.8M | 672.54M | 2.61B | 2.82B |
| High Estimate | 681.54M | 728.22M | 3.26B | 3.32B |
| Year Ago Sales | -- | 608.68M | 2.42B | 2.76B |
| Sales Growth (year/est) | -- | 13.70% | 14.20% | 12.30% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.23 | 0.23 | 0.23 | 0.34 |
| EPS Actual | 0.29 | 0.21 | 0.11 | 0.46 |
| Difference | 0.06 | -0.02 | -0.12 | 0.12 |
| Surprise % | 26.10% | -8.70% | -52.20% | 35.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.35 | 0.47 | 1.72 | 2.63 |
| 7 Days Ago | 0.37 | 0.43 | 1.6 | 2.71 |
| 30 Days Ago | 0.37 | 0.43 | 1.65 | 2.79 |
| 60 Days Ago | 0.39 | 0.44 | 1.7 | 2.81 |
| 90 Days Ago | 0.42 | 0.45 | 2.06 | 3.24 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 7 | 14 | 17 | 10 |
| Up Last 30 Days | 7 | 14 | 18 | 9 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 11 | 3 | 2 | 8 |
Growth Estimates
| CURRENCY IN USD | BMRN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 20.70% | -- | -- | 6.50% |
| Next Qtr. | 123.80% | -- | -- | 12.00% |
| Current Year | 97.70% | -- | -- | 5.30% |
| Next Year | 52.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 43.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -0.19% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Morgan Stanley: Overweight to Overweight | 4/26/2024 |
| Maintains | Canaccord Genuity: Hold to Hold | 4/26/2024 |
| Maintains | Citigroup: Neutral to Neutral | 4/25/2024 |
| Maintains | Scotiabank: Sector Perform to Sector Perform | 4/25/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/25/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 4/25/2024 |
Related Tickers
INCY Incyte Corporation
51.68
+0.98%
SRPT Sarepta Therapeutics, Inc.
128.77
+1.08%
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
REGN Regeneron Pharmaceuticals, Inc.
883.20
-0.84%
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%
SAGE Sage Therapeutics, Inc.
13.69
+0.81%
BGNE BeiGene, Ltd.
153.58
+3.38%